Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Samantha J Mayo, RN, PhD, Hans A. Messner, MD/PhD, Sean B. Rourke, PhD, Doris Howell, RN PhD, J. Charles Victor, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, Laura McGillis, BScN, MN, RN(EC), CONc, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Naheed Alam, MBBS,MD, Anna Lambie, RN NP, Dawn Breen, RN, David Loach, MD, Christine Piescic, RN, Kelly Metcalfe, RN PhD

Blood (2015) 126 (23): 3289.

https://doi.org/10.1182/blood.V126.23.3289.3289

Published: 2015

Journal Articles

Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Hans A. Messner, MD/PhD, Naheed Alam, MBBS,MD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Anna Lambie, RN NP, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 3201.

https://doi.org/10.1182/blood.V126.23.3201.3201

Published: 2015

Journal Articles

Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission

Fotios V. Michelis, MDPhD, Hans A. Messner, MD/PhD, Naheed Alam, MBBS,MD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MD PhD, John Kuruvilla, MD, Anna Lambie, RN NP, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 2020.

https://doi.org/10.1182/blood.V126.23.2020.2020

Published: 2015

Journal Articles

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Justyna Bartoszko, Tony Panzerella, Anthea Lau, Naheed Alam, MBBS,MD, Aaron D Schimmer, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Andre C Schuh, MD FRCPC, Mohamed Shanavas, MD FRACP, FRCPA, Karen W.L. Yee, MDFRCPC, Vikas Gupta, MD FRCP, FRCPath

Blood (2014) 124 (21): 3180.

https://doi.org/10.1182/blood.V124.21.3180.3180

Published: 2014

Journal Articles

Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation

Marc Poch Martell, MD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Vikas Gupta, MD FRCP, FRCPath, Jeffrey H. Lipton, MD PhD, John Kuruvilla, MD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD, Dennis Kim, MDPhD

Blood (2014) 124 (21): 3936.

https://doi.org/10.1182/blood.V124.21.3936.3936

Published: 2014

Journal Articles

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Fotios V. Michelis, MDPhD, Hans A. Messner, MD PhD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, David Loach, MD, Laura McGillis, NP, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis D. Kim, MD PhD

Blood (2014) 124 (21): 2529.

https://doi.org/10.1182/blood.V124.21.2529.2529

Published: 2014

Journal Articles

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., Andre C Schuh, MD FRCPC, Mark D Minden, MDPhD, Aaron D Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS, MD, Andrzej Lutynski, MD, Amr Rostom, MD CFPC, Anna Rydlewski, MD, Karen Yee, MD

Blood (2014) 124 (21): 5285.

https://doi.org/10.1182/blood.V124.21.5285.5285

Published: 2014

Journal Articles

A Standard, 3-Tube, 10-Color Flow Cytometry Panel for Acute Myeloid Leukemia Diagnosis Can be Used for MRD Detection at Day 30 after Induction, and Is Predictive of Early Relapse

Naheed Alam, MBBS,MD, Anne Tierens, MD PhD, Karen Yee, MD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Anna Porwit, MDPhD, Andre C Schuh, MD FRCPC

Blood (2014) 124 (21): 5336.

https://doi.org/10.1182/blood.V124.21.5336.5336

Published: 2014

Journal Articles

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Mohamed Shanavas, MD FRACP, FRCPA, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Eshetu G Atenafu, MSc, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Vikas Gupta, MD MRCP, FRCPath, Dennis Kim, MD PhD

Blood (2014) 124 (21): 5927.

https://doi.org/10.1182/blood.V124.21.5927.5927

Published: 2014

Journal Articles

Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm By Using 10-Colour Flow Cytometry and Achievement of Remission By Hypercvad Therapy

Uday Deotare, MD DM, Elizabeth Hyjek, MD PhD, Anna Porwit, MDPhD, Rumina Musani, MDFCAP, FRCPC, David Barth, MD FRCPC, Emina Torlakovic, MD, Anne Tierens, MD PhD, Aaron D Schimmer, MDPhD, Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS,MD, Karen W.L. Yee, MDFRCPC

Blood (2014) 124 (21): 2365.

https://doi.org/10.1182/blood.V124.21.2365.2365

Published: 2014

Journal Articles

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, MD, Naheed Alam, MBBS, MD, Anna Lambie, NP, Laura McGillis, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1237.

https://doi.org/10.1182/blood.V124.21.1237.1237

Published: 2014

Journal Articles

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Laura McGillis, NP, Anna Lambie, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1179.

https://doi.org/10.1182/blood.V124.21.1179.1179

Published: 2014

Journal Articles

Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Naheed Alam, MBBS,MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, David Loach, MD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, Anna Lambie, NP, Hans A. Messner, PhD

Blood (2014) 124 (21): 3955.

https://doi.org/10.1182/blood.V124.21.3955.3955

Published: 2014

Journal Articles

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Uday Deotare, MD DM, Marwan Shaheen, MD, Joseph M. Brandwein, MD FRCPC, Bethany Gill, BSc, MMath, Suzanne Kamel-Reid, PhD DABMG, FACMG, Karen W.L. Yee, MDFRCPC, Anna Rydlewski, MD, Andrzej Lutynski, MD, Amr Rostom, MDCFPC, Aaron D Schimmer, MDPhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS,MD, Andre C Schuh, MD FRCPC

Blood (2014) 124 (21): 3693.

https://doi.org/10.1182/blood.V124.21.3693.3693

Published: 2014

Journal Articles

A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Feras Alfraih, MD, John Kuruvilla, MD, Naheed Alam, MBBS,MD, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, David Loach, MD, Eshetu G Atenafu, M.Sc., Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 3877.

https://doi.org/10.1182/blood.V124.21.3877.3877

Published: 2014

Journal Articles

Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Naheed Alam, MBBS,MD, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, David Loach, MD, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 3879.

https://doi.org/10.1182/blood.V124.21.3879.3879

Published: 2014

Journal Articles

Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse

Joon Ho Moon, M.D., Ph.D., Sang Kyun Sohn, MD, PhD, Naheed Alam, MBBS, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 2066.

https://doi.org/10.1182/blood.V122.21.2066.2066

Published: 2013

Journal Articles

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

Naheed Alam, MBBS, Eshetu G Atenafu, MSc, Wei Xu, Ph.D., Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD, PhD

Blood (2013) 122 (21): 4613.

https://doi.org/10.1182/blood.V122.21.4613.4613

Published: 2013

Journal Articles

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Naheed Alam, MBBS, Anna Lambie, NP, Yvette Neme Yunes, MD, Feras Alfraih, MD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeff H Lipton, MD, Hans A. Messner, M.D./Ph.D

Blood (2012) 120 (21): 4501.

https://doi.org/10.1182/blood.V120.21.4501.4501

Published: 2012

NARROW

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Standard, 3-Tube, 10-Color Flow Cytometry Panel for Acute Myeloid Leukemia Diagnosis Can be Used for MRD Detection at Day 30 after Induction, and Is Predictive of Early Relapse

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm By Using 10-Colour Flow Cytometry and Achievement of Remission By Hypercvad Therapy

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation

Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only